The global interventional cardiology market is expected to surpass US$40 billion by the end of the decade.
As cardiovascular disease remains the world's leading cause of death, demand for minimally invasive therapies continues to accelerate across coronary intervention, structural heart, imaging and catheter-based therapies.
A handful of companies currently dominate the landscape.
What's interesting is how the market has evolved. Ten years ago, most would have expected the industry to remain dominated by US and Western European businesses.
Today, companies from Japan, China, India and Singapore have become major forces in global cardiovascular intervention.
Three trends are shaping the next decade: Structural heart: continues to be the fastest-growing segment, led by TAVR, mitral and tricuspid therapies.
Intravascular imaging and physiology-guided interventions: Becoming standard practice in leading centres.
Emerging market innovators are beginning to challenge established players on a global scale.
The companies above aren't simply selling devices.
They're shaping how cardiovascular disease is diagnosed and treated for millions of patients every year.
Which company do you think is best positioned to gain market share over the next five years?